QuantSignals › Forecasts › ZTS
KATY's daily model path, its record on ZTS, and the options read. Prices as of the Nov 10, 2026 close · page updated Nov 10, 2026.
Last close
$82.46
Nov 10, 2026 · +0.17% on the day
KATY call
BUY
run Nov 6, 2026
Path end (20 sessions)
$95.67
+20.49% from $79.40
Path range
+1.7% to +20.5%
lowest and highest point of the path
Replay record on ZTS
4/4 hits
100% · 0 misses
Options
CHEAP
IV 35% · 0.93× realized
KATY's latest public daily path for Zoetis, from its run on Nov 6, 2026, points up, which KATY labels BUY. Starting from the $79.40 close, the path ends 20 sessions later near $95.67 (+20.49%), around Dec 4, and ranges between +1.69% and +20.49% along the way. That is a model path, not a price target.
Since that run, ZTS has closed at $82.46 on Nov 10, 2026, +3.85% from the start, 2 of 20 sessions in. So far the move agrees with the path. The call is scored after session 20.
On ZTS, KATY's replay record is 4 hits and 0 misses in 4 tested calls (100%), above its 50.1% rate across all tickers. Its most recent completed replay call expected +33.65% and ZTS moved +6.14%: a hit on direction.
In options, the at-the-money 2026-12-18 contract trades at 35% implied volatility against about 37% realized, 0.93× realized, so options read cheap. That is a pricing read, not a signal.
Daily closes, with KATY's Nov 6, 2026 path drawn from its start close to its end point; the shaded wedge spans the path's lowest and highest points.
The KATY apps and extension show the newest ZTS path as soon as it runs, with the full step-by-step line on the chart. They are free to install; live forecasts need KATY Premium or an FST membership.
Every public ZTS path this page has captured, scored on the close 20 sessions after its start: a BUY is a hit if that close is higher, a SELL if it is lower.
| Run | Call | Start close | Path end | Outcome at 20 sessions |
|---|---|---|---|---|
| Nov 6, 2026 | BUY | $79.40 | $95.67 (+20.49%) | Open, 2/20 sessions · +3.85% so far |
4 hits, 0 misses in 4 replayed ZTS calls (100% on direction; 100% finished inside the 1.5% band; average path error 12.49%). Across all tickers KATY's replay hit rate is 50.1% over 1,023 calls (BUY > +1.5%, SELL < -1.5% on the 20-step path). Replays re-run the model on past data it did not see; they are not live trades.
KATY re-forecast the 20 sessions that just finished without seeing them. It expected +33.65%; the actual move was +6.14% (direction hit, average path error 9.4%).
| Step | Session | Model path | Actual close | Path vs actual |
|---|---|---|---|---|
| 1 | Oct 12, 2026 | $75.84 | $75.65 | +0.25% |
| 5 | Oct 16, 2026 | $79.30 | $79.38 | −0.10% |
| 10 | Oct 23, 2026 | $87.60 | $81.03 | +8.11% |
| 15 | Oct 30, 2026 | $93.67 | $79.72 | +17.50% |
| 20 | Nov 6, 2026 | $99.98 | $79.40 | +25.92% |
The at-the-money 2026-12-18 ZTS option (38 days) is priced at 34.8% implied volatility, 0.93× the stock's realized volatility, which reads cheap. Cheap or rich is a pricing read, not a signal. See the full options-value screen.
KATY's latest public daily path for ZTS (run Nov 6, 2026) is BUY: from $79.40 it ends near $95.67 (+20.49%) after 20 sessions. It is a model path, not a price target. The newest path is in the KATY apps (free to install; live forecasts need KATY Premium or an FST membership).
In replay, KATY called the direction of ZTS right 4 times and wrong 0 times out of 4 tested calls (100%). Public calls on this page are scored after 20 sessions and listed above, misses included.
KATY is a time-series foundation model that reads the recent daily bars of ZTS and draws the most likely path for the next 20 sessions. A path that ends more than 1.5% up is a BUY, more than 1.5% down a SELL, and anything in between is NEUTRAL. It is not investment advice.
KATY draws this forecast on your own charts: in TradingView with the Chrome extension, or on your phone. The extension and apps are free to install; live forecasts need KATY Premium or an FST membership.
Healthcare & biotech
Most viewed
Not investment advice. KATY's output is a model path, not a price target and not a recommendation to buy or sell. Model forecasts are often wrong; the hit and miss counts on this page are shown so you can judge that yourself. Trading involves risk of loss. Data from QS Research; prices are daily closes and may lag.